While I do have some concerns about the process by which FDA is proposing this new regulatory approach, patient groups have questioned whether there are gaps in the current system that are jeopardizing patients' safety.
Pitts expresses concerns about FDA's regulatory approach and patient safety issues.
Share
More from Joe Pitts
We will hear from witnesses on ways to address our trauma and emergency medical systems.
Trauma is the number-one cause of productive life years lost, greater than cancer or heart disease.
So, moving forward, the committee welcomes feedback on how we can improve care for children with medical complexity without disrupting the successful approaches already in place.
H.R. 1807, the Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2015, sponsored by Rep. Danny Davis (IL) and Rep. Michael Burgess (TX) reauthorizes a sickle cell disease demonstration program.
Other voices in this conversation
